Clare Market Investments LLC Buys Shares of 2,905 iShares Biotechnology ETF $IBB

Posted by ABMN Staff on Jul 7th, 2026

Clare Market Investments LLC bought a new position in iShares Biotechnology ETF (NASDAQ:IBB – Free Report) in the 1st quarter, according to its most recent filing with the SEC. The institutional investor bought 2,905 shares of the financial services provider’s stock, valued at approximately $490,000.

A number of other hedge funds and other institutional investors have also made changes to their positions in IBB. Darwin Wealth Management LLC bought a new stake in iShares Biotechnology ETF during the 2nd quarter valued at $25,000. Basepoint Wealth LLC acquired a new position in shares of iShares Biotechnology ETF during the fourth quarter worth $26,000. Cary Street Partners Financial LLC purchased a new stake in shares of iShares Biotechnology ETF during the fourth quarter worth about $29,000. Copia Wealth Management purchased a new position in shares of iShares Biotechnology ETF in the fourth quarter worth $34,000. Finally, Caitlin John LLC acquired a new position in shares of iShares Biotechnology ETF in the fourth quarter valued at about $34,000. Institutional investors own 62.45% of the company’s stock.

iShares Biotechnology ETF Stock Up 1.1%

Shares of IBB opened at $197.37 on Tuesday. The business’s 50-day moving average is $173.66 and its two-hundred day moving average is $172.05. iShares Biotechnology ETF has a fifty-two week low of $128.06 and a fifty-two week high of $197.37.

iShares Biotechnology ETF Cuts Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Thursday, June 18th. Shareholders of record on Monday, June 15th were issued a $0.0238 dividend. This represents a $0.10 annualized dividend and a yield of 0.0%. The ex-dividend date of this dividend was Monday, June 15th.

About iShares Biotechnology ETF

(Free Report)

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.